122P Dose escalation phase Ib trial of a new micellar docetaxel compound in patients with metastatic castration-resistant prostate cancer (mCRPC), SAKK 67/20
Docetaxel micellar (DM) is a novel formulation of docetaxel, with N-(all-trans-retinoyl)-L-cysteic acid methyl ester sodium salt (XMeNa) as excipient, not requiring pre/post infusional steroids. The study aimed to define safety, preliminary clinical activity and pharmacokinetics (PK) of DM in patients (pts) with mCRPC.
Authors
- S. Koolen
- S. M. Fischer
- Sebastjan Merlo
- C. Sessa
- Ursula Vogl (ORCID: https://orcid.org/0000-0002-2046-4246)
- Klaus Eckhardt (ORCID: https://orcid.org/0000-0002-5030-0971)
- A. Stathis
- M. Joerger
- P. J. M. Rietveld
- A. Omlin
- R. Cathomas
- I. Colombo
- Katrin Gobat
- D. Zoelly
Institutions
- Kantonsspital St. Gallen (CH)
- Institute of Oncology Research (CH)
- Swiss Group For Clinical Cancer Research (CH)
- Kantonsspital Graubünden (CH)
- Erasmus MC Cancer Institute (NL)
- GastroZentrum Hirslanden Zürich (CH)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.104284
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00